Cohen Klingenstein’s GSK GSK Stock Holding History

Cohen Klingenstein’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Hold	79,398	–	–	0.12%	83
2026 Q1	$4.38M	Hold	79,398	–	–	0.14%	75
2025 Q4	$3.89M	Hold	79,398	–	–	0.12%	78
2025 Q3	$3.43M	Hold	79,398	–	–	0.11%	86
2025 Q2	$3.05M	Hold	79,398	–	–	0.1%	91
2025 Q1	$3.08M	Sell	79,398 -18,800	-19%	-$688K	0.11%	87
2024 Q4	$3.32M	Sell	98,198 -6,114	-6%	-$220K	0.11%	85
2024 Q3	$4.26M	Sell	104,312 -828	-0.8%	-$33.9K	0.15%	89
2024 Q2	$4.05M	Sell	105,140 -13,200	-11%	-$555K	0.15%	86
2024 Q1	$5.07M	Sell	118,340 -5,600	-5%	-$231K	0.19%	79
2023 Q4	$4.59M	Sell	123,940 -8,400	-6%	-$302K	0.19%	80
2023 Q3	$4.8M	Sell	132,340 -16,000	-11%	-$568K	0.22%	70
2023 Q2	$5.29M	Hold	148,340	–	–	0.23%	71
2023 Q1	$5.28M	Hold	148,340	–	–	0.25%	70
2022 Q4	$5.21M	Sell	148,340 -20,851	-12%	-$695K	0.26%	70
2022 Q3	$4.98M	Sell	169,191 -9	-0%	-$341	0.26%	65
2022 Q2	$9.21M	Hold	169,200	–	–	0.46%	38
2022 Q1	$9.21M	Hold	169,200	–	–	0.38%	49
2021 Q4	$9.33M	Sell	169,200 -40,000	-19%	-$2.08M	0.37%	50
2021 Q3	$9.99M	Sell	209,200 -5,784	-3%	-$291K	0.44%	46
2021 Q2	$10.7M	Hold	214,984	–	–	0.46%	45
2021 Q1	$9.59M	Hold	214,984	–	–	0.44%	47
2020 Q4	$9.89M	Hold	214,984	–	–	0.49%	39
2020 Q3	$10.1M	Hold	214,984	–	–	0.57%	35
2020 Q2	$11M	Hold	214,984	–	–	0.67%	33
2020 Q1	$10.2M	Hold	214,984	–	–	0.75%	33
2019 Q4	$12.6M	Hold	214,984	–	–	0.73%	34
2019 Q3	$11.5M	Buy	214,984 +20,800	+11%	+$1.07M	0.72%	33
2019 Q2	$9.71M	Sell	194,184 -20,800	-10%	-$1.04M	0.69%	35
2019 Q1	$11.2M	Buy	214,984 +92,800	+76%	+$4.64M	0.78%	32
2018 Q4	$5.84M	Hold	122,184	–	–	0.88%	21
2018 Q3	$6.13M	Hold	122,184	–	–	0.78%	21
2018 Q2	$6.16M	Hold	122,184	–	–	0.84%	19
2018 Q1	$5.97M	Hold	122,184	–	–	0.85%	21
2017 Q4	$5.42M	Hold	122,184	–	–	0.77%	24
2017 Q3	$6.2M	Hold	122,184	–	–	0.94%	20
2017 Q2	$6.59M	Hold	122,184	–	–	1.03%	18
2017 Q1	$6.44M	Hold	122,184	–	–	1.03%	18
2016 Q4	$5.88M	Hold	122,184	–	–	1%	19
2016 Q3	$6.59M	Hold	122,184	–	–	1.14%	16
2016 Q2	$6.62M	Hold	122,184	–	–	1.22%	16
2016 Q1	$6.19M	Hold	122,184	–	–	1.17%	17
2015 Q4	$6.16M	Hold	122,184	–	–	1.15%	16
2015 Q3	$5.87M	Hold	122,184	–	–	1.16%	17
2015 Q2	$6.36M	Hold	122,184	–	–	1.14%	19
2015 Q1	$7.05M	Hold	122,184	–	–	1.29%	15
2014 Q4	$6.53M	Hold	122,184	–	–	1.23%	20
2014 Q3	$7.02M	Hold	122,184	–	–	1.24%	18
2014 Q2	$8.17M	Hold	122,184	–	–	1.56%	14
2014 Q1	$8.16M	Hold	122,184	–	–	1.62%	12
2013 Q4	$8.15M	Hold	122,184	–	–	1.62%	12
2013 Q3	$7.66M	Hold	122,184	–	–	1.67%	12
2013 Q2	$7.63M	Buy	+122,184	New	+$7.75M	1.78%	13

Other funds holding GSK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

FVWA

Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return

SIS

Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Cohen Klingenstein's GSK Position: Q2 2026 in Review

Cohen Klingenstein held its GSK (GSK) position steady in Q2 2026 at 79,398 shares worth $4.16M. The position accounts for 0.12% of the portfolio, ranked #83.

Cohen Klingenstein first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.6M in Q4 2019. 416 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Cohen Klingenstein held 79,398 shares of GSK worth $4.16M as of Q2 2026.
Cohen Klingenstein left its GSK share count unchanged in Q2 2026.
GSK made up 0.12% of Cohen Klingenstein's portfolio in Q2 2026, its #83 holding.
Cohen Klingenstein first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
Cohen Klingenstein's GSK position peaked at $12.6M in Q4 2019.
416 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cohen Klingenstein's 13F filing for Q2 2026, filed 15 Jul 2026.